Compare Cintas Corporation (CTAS) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cintas Corporation vs Cassava Sciences Inc — how do they compare? Cintas Corporation trades at $200.75 (market cap $79.86B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Cintas Corporation is far larger — about 2026.9× Cassava Sciences Inc's market cap, and Cintas Corporation pays a 1.03% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Cintas Corporation for 124 Days and Cassava Sciences Inc for 37 Days on average.
| CTAS | FLNA | |
|---|---|---|
Market Cap | $79.86B | $39.40M |
Volume | 1,323,583 | 759,018 |
Sector | Industrials | Health |
52-Week High | $216.53 | $4.64 |
52-Week Low | $163.55 | $0.68 |
Typical Hold Time | 124 Days | 37 Days |
Enterprise Value | $82.33B | -$43.28M |
Dividend Yield | 1.03% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cintas (CTAS) trades at $197.19, up 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2027 results with revenue of $3.01 billion, beating estimates, and raised full-year guidance. Fundamentals show robust revenue growth, expanding margins, and high profitability, though valuation multiples like a P/E of 39.67 are elevated. Analyst sentiment is moderately bullish with a consensus price target of $234.60.
The outlook for CTAS is positive, driven by durable growth, record margins, and strong capital returns. Key opportunities include consistent earnings beats and market leadership, while risks involve high valuation sensitivity and competitive pressures. The stock's upside potential is supported by analyst targets, but investors should monitor execution against guidance.
Filana Therapeutics (FLNA) trades at $0.82, down 6.77% today, amid bearish technical signals but with positive fundamental catalysts. The company shows improving quarterly EPS beats and a favorable EV/EBITDA of 1.03, though it remains unprofitable with negative cash flow. Recent FDA clearance for its epilepsy drug trial has generated optimism, reflected in strong analyst buy ratings (67% consensus).
The outlook balances clinical progress against financial strain. The FDA hold lift on simufilam provides a clear near-term catalyst for Phase 2a trials starting in 2027, supporting the bullish analyst view. However, high cash burn (-$33M net CF in 2025) and lack of revenue pose significant risks to sustainability, requiring careful monitoring of funding and trial milestones.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Cintas Corporation
In its core uniform and facility services unit (78% of sales), Cintas provides uniform rental programs to businesses across the size spectrum, mostly in North America. The firm is by far the largest provider in the industry. Facilities products generally include the rental and sale of entrance mat, mops, shop towels, hand sanitizers, and restroom supplies. Cintas also runs a first aid and safety services business (11% of sales), a fire protection services business (7% of sales), and a uniform direct sales business (4% of sales).
Read more on CTAS →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
